We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

128 hedge funds and large institutions have $980M invested in Aclaris Therapeutics in 2021 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

172% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 18

32% more funds holding

Funds holding: 97 → 128 (+31)

15% more call options, than puts

Call options by funds: $3.32M | Put options by funds: $2.88M

7% more ownership

Funds ownership: 87.68% → 94.68% (+7%)

6% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 32

14% less capital invested

Capital invested by funds: $1.14B → $980M (-$165M)

47% less funds holding in top 10

Funds holding in top 10: 15 → 8 (-7)

Holders
128
Holders Change
+31
Holders Change %
+31.96%
% of All Funds
2.23%
Holding in Top 10
8
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-46.67%
% of All Funds
0.14%
New
49
Increased
34
Reduced
32
Closed
18
Calls
$3.32M
Puts
$2.88M
Net Calls
+$440K
Net Calls Change
-$1.75M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.8M
2
BlackRock
BlackRock
New York
+$51.2M
3
BI
BVF Inc
California
+$22.7M
4
State Street
State Street
Massachusetts
+$19.9M
5
Holocene Advisors
Holocene Advisors
New York
+$19.8M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$27.3M
2
Invesco
Invesco
Georgia
-$20.2M
3
Renaissance Technologies
Renaissance Technologies
New York
-$12.6M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.54M
5
GTC
Ghost Tree Capital
New York
-$7.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
26
Laurion Capital Management
New York
$9.37M +$11.2M +493,962 +1,244%
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$8.4M +$3.43M +150,800 +46%
Northern Trust
28
Northern Trust
Illinois
$8.02M +$7.9M +347,641 +320%
Two Sigma Investments
29
Two Sigma Investments
New York
$6.59M +$4.57M +201,226 +116%
FM
30
Frazier Management
Washington
$6.51M -$7.39M -325,267 -47%
O
31
OrbiMed
New York
$6.36M +$8.22M +362,000 New
Deutsche Bank
32
Deutsche Bank
Germany
$5.87M +$1.72M +75,523 +29%
Goldman Sachs
33
Goldman Sachs
New York
$5.71M +$4.65M +204,693 +170%
ACM
34
Asymmetry Capital Management
California
$5.55M +$7.17M +315,834 New
AAA
35
Affinity Asset Advisors
New York
$4.83M +$1.2M +52,733 +24%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$4.73M +$6.12M +269,255 New
SSA
37
Schonfeld Strategic Advisors
New York
$4.47M -$2.57M -113,048 -31%
GTC
38
Ghost Tree Capital
New York
$4.39M -$7.95M -350,000 -58%
DGM
39
Darwin Global Management
Jersey
$4.39M +$5.68M +250,000 New
Nomura Holdings
40
Nomura Holdings
Japan
$4.22M – – –
Millennium Management
41
Millennium Management
New York
$3.52M -$3.25M -142,883 -42%
N
42
Nuveen
North Carolina
$3.23M +$4.17M +183,787 New
AI
43
Atom Investors
Texas
$3.21M +$4.15M +182,590 New
ACP
44
Acuta Capital Partners
California
$3.07M -$3.24M -142,730 -45%
IHAM
45
Integral Health Asset Management
New York
$3.07M +$3.98M +175,000 New
Balyasny Asset Management
46
Balyasny Asset Management
Illinois
$2.71M +$3.51M +154,420 New
Bank of New York Mellon
47
Bank of New York Mellon
New York
$2.38M +$547K +24,086 +22%
BCM
48
Bridgeway Capital Management
Texas
$2.37M -$1.8M -79,300 -37%
ECM
49
Endurant Capital Management
California
$2.1M -$7.63M -336,007 -74%
PCM
50
Pinz Capital Management
New York
$2.02M +$2.61M +114,835 New
1
2
3 4 5

ACRS Hedge Fund Activity: Q2 2021 in Review

128 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2021, worth a combined $980M — down 14% from $1.14B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new ACRS positions and 18 closed out — a net gain of 31 holders — while 34 added to existing stakes and 32 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $87.8M. The largest seller was Adage Capital Partners, cutting an estimated $27.3M.

  • 128 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2021, up from 97 in Q1 2021.
  • Funds reported $980M of Aclaris Therapeutics stock for Q2 2021, down 14% quarter-over-quarter.
  • 49 funds opened new Aclaris Therapeutics positions in Q2 2021 and 18 closed out, a net change of +31 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2021 was Wellington Management Group, an estimated $87.8M added.
  • The largest Aclaris Therapeutics seller in Q2 2021 was Adage Capital Partners, an estimated $27.3M sold.

Based on aggregated 13F filings for Q2 2021.